ALT Altimmune
- 7.260
- +0.060+0.83%
- 7.270
- +0.010+0.14%
Altimmune News
Altimmune Statement on the Passing of Dr. Stephen Harrison
GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected
TikTok to Restrict Weight Loss Drug Promotion
Popular social media platform TikTok is cracking down on most content related to weight loss drugs starting next month, according to the video-sharing site's new community guidelines published last week.
More contests are coming! Global Data: 13 new weight loss drugs are expected to be launched by 2029
Pharmacists are preparing to launch around 13 new weight loss treatments in the US within the next five years due to a surge in demand for weight loss products, according to a new report from global data analysis and consulting firm Global Data.
13 New Obesity Drugs Could Hit the Market by 2029 Amid Surging Demand
Drugmakers are preparing to launch an estimated 13 new weight-loss treatments in the U.S. over the next five years amid surging demand for the products, according to a new report by Global Data.
How Is The Market Feeling About Altimmune?
Altimmune's (NYSE:ALT) short percent of float has risen 15.72% since its last report. The company recently reported that it has 12.51 million shares sold short, which is 17.81% of all regular shares t
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Altimmune (NASDAQ:ALT) has outperformed the market over the past 5 years by 11.42% on an annualized basis producing an average annual return of 23.99%. Currently, Altimmune has a market capitalization
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Express News | HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $12
Altimmune's Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Investors might want to bet on Altimmune, Inc. (ALT), as it has been recently upgraded to a Zacks Rank #2 (Buy).
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphic.)
Express News | B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Altimmune Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/28/2024 95.12% B. Riley Securities $20 → $20 Reiterates Buy → Buy 02/13/2024 95.12% B. Riley Securities
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
An Intrinsic Calculation For Altimmune, Inc. (NASDAQ:ALT) Suggests It's 39% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Altimmune fair value estimate is US$14.49 Altimmune's US$8.89 share price signals that it might be 39% undervalued Analyst price target fo
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Q4 2023 Altimmune Inc Earnings Call
Buy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservation
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Analysis
Price Target
No Data
